Screener
Whitehawk Therapeutics WHWK Total Revenue
Total Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Whitehawk Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Whitehawk Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212075
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue | ||
| Product sales, net | — | $7,145 |
| Total revenue | — | 7,145 |
| Operating expenses | ||
| Selling, general and administrative | 6,290 | 12,815 |
| Research and development | 17,232 | 8,788 |
| Cost of goods sold | — | 760 |
| Total operating expenses | 23,522 | 22,363 |
Item 1. Financial Statements.
FAQ
- What is Whitehawk Therapeutics's total revenue?
- Whitehawk Therapeutics (WHWK) reported total revenue of $0 in Q1 2026.
- How has Whitehawk Therapeutics's total revenue changed year-over-year?
- Whitehawk Therapeutics's total revenue decreased by 100.0% year-over-year, from $7.15M to $0.
- What is the long-term trend for Whitehawk Therapeutics's total revenue?
- Over 3 years (2021 to 2025), Whitehawk Therapeutics's total revenue has grown at a -20.1% compound annual growth rate (CAGR), from $14M to $7.15M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Whitehawk Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude